Mainz Biomed (MYNZ) Issues H1 2022 Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Mainz Biomed Provides Corporate Update for First Half of 2022
July 5, 2022 3:01 AM EDTBERKELEY, Calif. and MAINZ, Germany, July 05, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ) (Mainz Biomed or the Company), a molecular genetics diagnostic company specializing in the early detection of cancer, is pleased to host a webcast on July 12, 2022 at 4:00pm ET to provide an update on the Companys progress for the first half of 2022, and to outline the plan for the balance of the fiscal year.
The webcast will offer the investment community a comprehensive briefing by Mainzs executive management team on the Companys flagship product ColoAlert, a highly... More
